

CORRIGENDUM to the Licence Agreement of 8 May 2026

THIS CORRIGENDUM TO THE LICENCE AGREEMENT OF 8 MAY 2026 (the “**Corrigendum**”) is entered into as of the date of last signature hereto, by and between:

F. HOFFMANN-LA ROCHE LTD, a company incorporated under the laws of Switzerland and having its registered office at Grenzacherstrasse 124, CH-4070 Basel, Switzerland (“**Roche**”);

and

MEDICINES PATENT POOL FOUNDATION, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at Rue de Varembe 7, CH-1202 Geneva (“**MPP**”),

each individually a “**Party**” and together the “**Parties**”.

RECITALS

WHEREAS the Parties entered into a Licence Agreement on 8 May 2026 (the “**Agreement**”);

WHEREAS the Parties acknowledge and agree that there are certain inadvertent clerical errors in the Appendices to Schedule 1 of the Agreement, including the listing of a licensed patent in the incorrect Appendix and a typographical error in an email address;

WHEREAS the Parties now wish to correct said errors in Schedule 1 of the Agreement; namely, to (i) transfer a Malaysian patent application from Appendix D (‘The Non-Territory Patents’) to Appendix C (‘The Patents’), and (ii) correct a typographical error in the MPP Pharmacovigilance email address set out in Appendix E.

NOW THEREFORE, based on the foregoing premises and in consideration of the mutual covenants and obligations contained herein and other good and valuable consideration, the receipt, adequacy, and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

AGREEMENT

1. **Interpretation.** Capitalised terms used but not defined in this Corrigendum shall have the meaning given to them in the Agreement. Unless otherwise stated, references to “Clause(s)”, “Schedule(s)” and “Appendix(-ces)” are references to the clauses, schedules, and appendices of and to the Agreement.
2. **Corrigendum.** The Agreement is hereby corrected, with retroactive effect from the Effective Date of the Agreement, as follows:
 - 2.1. Appendices C and D to Schedule 1 are corrected such that (i) the row containing the Malaysian patent application no. PI2021004656 in Family “8” is deleted in its entirety from Appendix D, and (ii) this row is inserted in its entirety into Appendix C between Family “7” and Family “9”:

8	Malaysia	PI2021004656	12-Mar-2019	30-Oct-2025	MY-210958-A	TREATING INFLUENZA USING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF IN A SUBJECT HAVING INFLUENZA AND A COMPLICATION RISK FACTOR
---	----------	--------------	-------------	-------------	-------------	--

2.2. Appendix E of the Agreement is corrected such that all instances of “pv@mppf.prg” in Table 2 are removed and replaced with “pv@mppf.org”.


3. General.

- 3.1. Variation. No provision of this Corrigendum may be modified or amended except expressly in writing signed by the Parties.
- 3.2. Governing law. The provisions of Clause 8 of the Agreement (*Governing Law and Jurisdiction*) are hereby incorporated into this Corrigendum as if set out herein.
- 3.3. Execution. This Corrigendum may be executed in any number of counterparts, each of which will be considered an original, and together will constitute one agreement. This Corrigendum may be executed using electronic signature, and an electronic record (e.g., a photographic, scanned, or facsimile copy) of the Corrigendum will have the same effect as an original hard copy.

IN WITNESS WHEREOF the Parties have executed this Corrigendum by their duly authorised representatives.

Signed for and on behalf of:


F. HOFFMANN-LA ROCHE LTD

Signature 
Name Tamara Schudel
Position Head of Global Policy & Advocacy
Date 06 August 2026

Signature 
Name Markus Hasselblatt
Position Global Portfolio Leader
Date 07 August 2026

Signed for and on behalf of:

MEDICINES PATENT POOL FOUNDATION

Signature 
Name Charles Gore
Position Executive Director
Date 06 August 2026